Home | About IJMPO | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |  Reader Login
Indian Journal of Medical and Paediatric Oncology
Search Article 
Advanced search 
Export selected to
Reference Manager
Medlars Format
RefWorks Format
BibTex Format
  Access statistics : Table of Contents
   2002| January-March  | Volume 23 | Issue 1  
    Online since May 30, 2009

  Archives   Previous Issue   Next Issue   Most popular articles   Most cited articles
Hide all abstracts  Show selected abstracts  Export selected to
  Viewed PDF Cited
Vertebral collapse as a presenting feature in a patient of acute lymphoblastic leukaemia.
PP Bapsy, P Kumar, C Haritha, Senthil, G Babu, VL Devi, S Bishnoi
January-March 2002, 23(1):8-8
Vertebral compression fracture is a rare complication of acute lymphoblastic leukaemia. Vertebral compression leading to paraparesis as a presenting feature is very rare. This rare case has been presented here.
[ABSTRACT]   Full text not available   
  664 0 -
Comparison of 5-fluorouracil and leucovorin versus 5-fluorouracil, leucovorin and oxaliplatin in measurable metastatic colorectal malignancy.
Yas V V, KM Patel, PM Shah, SN Shukla, BJ Parikh, AS Anand, SS Talati, SA Shah, B Parekh, S Nath, HP Panchal, AA Patel, B Shah, S Thuruthal, P Mehta
January-March 2002, 23(1):4-7
Colorectal carcinoma (CRC) accounts for 2.3 per cent of all cancers in our Institute as against 9.4 per cent at the international level. Of all deaths due to cancer at GCRI, 2.4 per cent deaths are attributed to CRC as against 7.9 per cent in the global the statistics. Due to lack of other active agents, 5-fluorouracil and leucovorin remained the treatment option over many years. Recently, positive results have been reported with addition of oxaliplatin to 5-fluorouracil and leucovorin. From March 1999 to September-2000, 32 patients were enrolled, 15 in the arm A containing 5-fluorouracil and leucovorin and 17 in the arm B containing 5-fluorouracil, leucovorin and oxaliplatin in measurable metastatic colorectal malignancy. No complete response was observed in either of the arms. Partial response was seen in 27 per cent in the arm A and 33.3 per cent in the arm B. The median duration of progression free survival in partial responders in the arm B it was 10 months, the difference, however, is not statistically significant as observed by log rank test (p=0.02342). To conclude, the addition of oxaliplatin to standard 5-fluorouracil and leucovorin increases the response rate, median progression free survival and overall survival, but none of these changes reached the statistical significance.
[ABSTRACT]   Full text not available   
  651 0 -
Ankylosing spondylitis associated with male breast cancer.
K Pavithran, DC Doval, R Kumar, KK Pandey
January-March 2002, 23(1):9-10
Malignancies have rarely been reported in patients with ankylosing spondylitis either as a complication of therapy or de novo. Here we report a 60-year-old male with ankylosing spondylitis who developed breast cancer during the course of his illness.
[ABSTRACT]   Full text not available   
  647 0 -
Hodgkin's disease and astrocytoma presenting synchronously in a young patient.
PP Bapsy, P Kumar, C Haritha, R Senthil, G Babu, S Balu
January-March 2002, 23(1):17-18
A rare case, in which cerebellar astrocytoma and Hodgkin's disease both were present simultaneously, is reported here.
[ABSTRACT]   Full text not available   
  644 0 -
Alpha interferon-2b as a modulator of ifosfamide plus cisplatin induction chemotherapy for advanced head & neck.
VR Pai, DK Hiwase, AT Mazumdar, DM Parikh, RC Mistry
January-March 2002, 23(1):13-16
We have reported a response rate of 65.7 per cent with ifosfamide and cisplatin combination in the treatment of advanced head and neck cancer.6 there have been promising new preliminary data to show that interferon with combination with chemotherapy can produce good response rate in patients with advanced head and neck cancer. Methods: All the patients with locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN) are entered in this study. Eligible patients had to have histologically proven SCCHN, no prior chemotherapy, measurable disease, WHO performance status 0-2 normal renal, liver function, WBC greater than 4000, platelet count greater than 100,000 and Haemoglobin greater than 10gm. Treatment Plan: All patients were treated with ifosfamide 1.5 gm/m2 IV infusion D1 to D5, inj. mesna 400 mg iv push at 0, 4, 8 hours on D1 to D5, inj cisplatin 20 mg infusion on D1 to D5 and inj alpha interferon-2b 3 mu subcutaneously on D1 to D5. Tab paracetamol 500 mg PO was given thirty minute prior to alpha-interferon therapy. The cycle was repeated every four weeks and such three cycles were administered. After completion of three cycles of chemotherapy, patients were assessed for response. Patients with complete response (CR), partial response (PR) and stable disease were evaluated for radiotherapy/surgery, whereas patients with progressive disease were treated symptomatically. Results: Between 1993 and 1994, 75 patients of advanced head and neck cancer were entered in the study. There were 67 males and 8 females and their median age was 50 (12-72) years. At the end of three cycles, 53 patients were evaluable for chemotherapy response. We have observed 9 CR, 30 PR and overall response was 73.6 percent. The median duration of response was 6 (1 to 36) months. Adverse effects of chemotherapy were generally well tolerated and reversible. All patients experienced nausea, vomiting, alopecia and flu-like syndrome. There was no dose limiting haematological toxicity. Conclusion: In the current study, the overall response rate is 39/53 (73.6 per cent), which is better than our previous (response rate 65.71 per cent) study in which ifosfamide with cisplatin was used. We conclude that the alpha interferon-2b improved response rate of combination of cisplatin and ifosfamide in patients with advanced head and neck cancer, without much toxicity.
[ABSTRACT]   Full text not available   
  637 0 -
Trophoblastic malignancies unrelated to pregnancy : a report of two cases.
A Chandra, SG Raman, TG Sagar, A Ramanujam, SS Singh
January-March 2002, 23(1):11-12
Trophoblastic disease is usually related to pregnancy. Since the advent of modern chemotherapy, trophoblastic tumour has become one of the most curable malignancies. Trophoblastic disease can develop independently of gestation, but this is very rare. This case reports two unusual cases of metastatic choriocarcinoma several years after menopause and their last pregnancies. They demonstrated chemoresistance to the different chemotherapy regimens and died from advanced metastatic disease.
[ABSTRACT]   Full text not available   
  608 0 -
Prognosis in colon malignancy (editorial).
SN Shukla
January-March 2002, 23(1):1-3
Full text not available   
  304 0 -